Interaction entre Suvorexant et Triazolam
Suvorexant et Triazolam : les deux notices de prescription signalent cette association dans les termes les plus forts, tels qu'une contre-indication, une mise en garde encadrée ou une consigne de l'éviter.
Ne pas associer sans l'avis d'un prescripteur. Les termes de la notice cités ci-dessous sont les plus forts qu'emploie la FDA.
Ce que disent les notices FDA
D'après la notice Triazolam · version du 2026-07-10
• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs.
Strong CYP 3A Inhibitors Triazolam is contraindicated in patients receiving strong inhibitors of CYP 3A such as ketoconazole, itraconazole, nefazodone, ritonavir, indinavir, nelfinavir, saquinavir, and lopinavir [see Contraindications (4) , Drug Interactions (7.1) ] .
Prevention or management Do not administer triazolam with a strong CYP3A4 inhibitor [see Contraindications (4) , Warnings and Precautions (5.8) ].
The use of alcohol and other central nervous system (CNS) depressants with sedative-hypnotics appears to increase the risk, as well as doses exceeding the maximum recommended dose.
Although behaviors such as sleep-driving may occur with sedative-hypnotics alone at recommended dosages, the use of alcohol and other central nervous system (CNS) depressants with sedative-hypnotics appears to increase the risk of such behaviors, as does the use of sedative-hypnotics at doses exceeding the maximum recommended dose.
D'après la notice Suvorexant (BELSOMRA) · version du 2025-03-10
CNS Depressant Effects and Daytime Impairment: Risk of impaired alertness and motor coordination, including impaired driving; risk increases with dose; caution patients taking 20 mg against next-day driving and other activities requiring complete mental alertness ( 5.1 ).
Prescribers should monitor for somnolence and CNS depressant effects, but impairment can occur in the absence of symptoms, and may not be reliably detected by ordinary clinical exam (i.e., less than formal testing of daytime wakefulness and/or psychomotor performance).
Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression.
Dosage adjustments of BELSOMRA and of concomitant CNS depressants may be necessary when administered together because of potentially additive effects.
The risk of next-day impairment, including impaired driving, is increased if BELSOMRA is taken with less than a full night of sleep remaining, if a higher than the recommended dose is taken, if co-administered with other CNS depressants, or if co-administered with other drugs that increase blood levels of BELSOMRA.
Vous prenez autre chose que ces deux-là ? Les interactions se cumulent. Vérifiez toute votre liste en une fois ; elle reste dans votre navigateur.
Ouvrir dans le vérificateurCeci n'est pas un avis médical. Interaction Checker cite le texte des notices FDA et des fiches d'information du NIH. L'importance d'une interaction dans votre cas dépend des doses, des horaires de prise, de la fonction rénale et hépatique et d'autres problèmes de santé. Vérifiez auprès d'un pharmacien ou d'un prescripteur.